title: Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.
authors: W E
authors: WE
authors: Bunney
authors: D L
authors: DL
authors: Azarnoff
authors: B W
authors: BW
authors: Brown
authors: R
authors: R
authors: Cancro
authors: R D
authors: RD
authors: Gibbons
authors: J C
authors: JC
authors: Gillin
authors: S
authors: S
authors: Hullett
authors: K F
authors: KF
authors: Killam
authors: D J
authors: DJ
authors: Kupfer
authors: J H
authors: JH
authors: Krystal
authors: P D
authors: PD
authors: Stolley
authors: G S
authors: GS
authors: French
authors: A M
authors: AM
authors: Pope
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D002908:Chronic Disease; D017277:Drug Approval; D004341:Drug Evaluation / Q000592:standards; D005069:Evaluation Studies as Topic; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects* / Q000627:therapeutic use; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D015995:Prevalence; D011358:Product Surveillance, Postmarketing; D011367:Professional Staff Committees; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D012107:Research Design / Q000592:standards; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000453:epidemiology; D014229:Triazolam / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D006993:Hypnotics and Sedatives; D014229:Triazolam